Evaluate the Efficacy and Safety of Pasireotide LAR (Long Acting Release) on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.

NCT01283542 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
20
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals